Catherine M Lockhart

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 7

Top Venues

Pharmacoepidemiology and drug safety

Journal of medical economics

Drugs - real world outcomes

Pharmacology research & perspectives

Biologics and Biosimilars Collective Intelligence Consortium

University of Washington (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Biologics and Biosimilars Collective Intelligence Consortium Jan 16 2018

United States

Executive Director

Education History

University of Washington

United States

MSC :: Pharmacy

Univesity of Washington

United States

PHD :: Pharmaceutics

University of Idaho

United States

BSC :: Visual Communications

Publications

Catherine M Lockhart, Cara L McDermott, Aaron B Mendelsohn, James Marshall, Ali McBride, Gary Yee, Minghui Sam Li, Aziza Jamal-Allial, Djeneba Audrey Djibo, Gabriela Vazquez Benitez, Terese A DeFor, Pamala A Pawloski
Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm. Journal of medical economics 26 (1) (2023)
Catherine M Lockhart, Cara L McDermott, Aaron B Mendelsohn, James Marshall, Ali McBride, Gary Yee, Minghui Sam Li, Aziza Jamal-Allial, Djeneba Audrey Djibo, Gabriela Vazquez Benitez, Terese A DeFor, Pamala A Pawloski
Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm. Journal of medical economics (2023)
Aaron B Mendelsohn, James Marshall, Cara L McDermott, Pamala A Pawloski, Jeffrey S Brown, Catherine M Lockhart
Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product. Drugs - real world outcomes 8 (2) (2021)
Aaron B Mendelsohn, Young Hee Nam, James Marshall, Cara L McDermott, Bharati Kochar Ms, Michael D Kappelman, Jeffrey S Brown, Catherine M Lockhart
Utilization patterns and characteristics of users of biologic anti-inflammatory agents in a large, US commercially insured population. Pharmacology research & perspectives 9 (1) (2021)
Jie Zhang, Kevin Haynes, Aaron B Mendelsohn, James Marshall, Charles E Barr, Cara McDermott, Jeffrey Brown, Annemarie Kline, James Kenney, Katelyn J King, Cynthia Holmes, Kai Yeung, John Barron, Huifeng Yun, Catherine M Lockhart
Capture of biologic and biosimilar dispensings in a consortium of U.S.-based claims databases: Utilization of national drug codes and Healthcare Common Procedure Coding System modifiers in medical claims. Pharmacoepidemiology and drug safety 29 (7) (2019)
Catherine M Lockhart, Cara L McDermott, Thomas Felix, Nancy D Lin, Mark J Cziraky, Aaron B Mendelsohn, Jeffrey S Brown
Barriers and facilitators to conduct high-quality, large-scale safety and comparative effectiveness research: The Biologics and Biosimilars Collective Intelligence Consortium experience. Pharmacoepidemiology and drug safety 29 (7) (2019)
Mengdong He, Adrian J Santiago Ortiz, James Marshall, Aaron B Mendelsohn, Jeffrey R Curtis, Charles E Barr, Catherine M Lockhart, Seoyoung C Kim
Mapping from the International Classification of Diseases (ICD) 9th to 10th Revision for Research in Biologics and Biosimilars Using Administrative Healthcare Data. Pharmacoepidemiology and drug safety 29 (7) (2019)

Catherine M Lockhart.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Catherine M Lockhart